GlassScriptPhysician profile
Glen A Reznikoff
NPI 1457348088
$27,990.52
in general payments reported to CMS, 2019-2025
70 companies · $5,960 in 2025
The $5,960 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,330 · 2020: $4,132 · 2021: $1,535 · 2022: $4,588 · 2023: $660 · 2024: $5,786 · 2025: $5,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,556 · Consulting Fee: $3,823 · Travel and Lodging: $2,468 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.62 |
| Consulting Fee | $3,822.50 |
| Travel and Lodging | $2,467.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,242.24 | 2019-2022 | |
| Geron Corporation | $3,773.88 | 2025 | Imetelstat, Rytelo |
| Ipsen Biopharmaceuticals, INC | $3,515.41 | 2019-2025 | Tazverik, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $2,278.29 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $2,130.43 | 2019-2025 | Erleada, Darzalex, Akeega |
| Pfizer INC. | $841.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $783.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $712.91 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $599.32 | 2019-2020 | |
| Genentech USA, INC. | $534.19 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Celgene Corporation | $531.44 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $524.38 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Astellas Pharma US INC | $473.94 | 2019-2025 | Padcev, Xospata, Vyloy |
| Genzyme Corporation | $430.17 | 2019-2025 | |
| Daiichi Sankyo INC. | $385.58 | 2019-2024 | Injectafer |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Reznikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.